<DOC>
	<DOCNO>NCT00197080</DOCNO>
	<brief_summary>The purpose study assess efficacy safety ropinirole XR treatment adult Restless Legs Syndrome ( RLS ) .</brief_summary>
	<brief_title>Ropinirole XR ( Extended Release ) In Patients With Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criterion : Diagnosed RLS use International RLS Study Group Diagnostic Criteria total score 15 great International RLS Rating Scale . Have even nighttime symptom RLS , significant sleep impairment due RLS symptom , symptom require treatment prior bedtime , early 5:00PM . Exclusion criterion : Have secondary RLS . Have medical condition may impact efficacy assessment may present safety concern .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
</DOC>